Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-05-16 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2024-05-16 English
Financial Result Updates
Regulatory Filings
2024-05-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) disclosing a Show Cause Notice received from the Goods and Service Tax (GST) Authority. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to continuous disclosure obligations for listed companies. The document details the nature of the notice, the authority involved, the period concerned (2019-2020), and the potential financial impact. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory disclosure about a legal/tax matter, not a full audit report or annual/interim report. It is not a report publication announcement since it contains substantive disclosure. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-05-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming earnings conference call for the fourth quarter and full year ended March 31, 2024. It includes details about the call schedule, participants, and dial-in information. The document does not contain any financial results or substantive financial data itself, but rather announces the event where such results will be discussed. The document length is 3656 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript announcement (CT) or possibly a Regulatory Filing (RNS). However, since it specifically announces an earnings conference call, the most appropriate classification is Call Transcript (CT) as it relates directly to the earnings call event.
2024-05-08 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying about an upcoming Board Meeting scheduled for May 16, 2024. The purpose of the meeting includes considering and approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2024, and recommending a final dividend. The letter references compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures related to board meetings. The document does not contain the financial results themselves but is an announcement of the board meeting where such results will be approved and possibly announced. The document is short (1870 characters) and serves as an intimation rather than a report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2024-05-08 English
Board Meeting — INDOCO REMEDIES LIMITED has informed the Exchange about Board Meeting to be held on 16-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the per…
Regulatory Filings
2024-05-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.